Literature DB >> 10932141

CD18 trials disappoint again.

A Dove.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10932141     DOI： 10.1038/78412

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  21 in total

Review 1.  New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.

Authors:  Wendy Weston; Vineet Gupta; Rebecca Adkins; Roland Jurecic
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Multivessel myocardial infarction: a window to future treatments of myocardial infarction.

Authors:  Philip D Houck; Walter J Linz
Journal:  Heart Asia       Date:  2010-08-26

3.  High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding.

Authors:  Mohd Hafeez Faridi; Dony Maiguel; Brock T Brown; Eigo Suyama; Constantinos J Barth; Michael Hedrick; Stefan Vasile; Eduard Sergienko; Stephan Schürer; Vineet Gupta
Journal:  Biochem Biophys Res Commun       Date:  2010-02-25       Impact factor: 3.575

4.  Agonist leukadherin-1 increases CD11b/CD18-dependent adhesion via membrane tethers.

Authors:  Emrah Celik; Mohd Hafeez Faridi; Vinay Kumar; Shashank Deep; Vincent T Moy; Vineet Gupta
Journal:  Biophys J       Date:  2013-12-03       Impact factor: 4.033

Review 5.  Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species.

Authors:  Hartmut Jaeschke; Benjamin L Woolbright
Journal:  Transplant Rev (Orlando)       Date:  2012-04       Impact factor: 3.943

6.  P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo.

Authors:  Edith Hochhauser; Ronit Cohen; Maayan Waldman; Anna Maksin; Ahuva Isak; Dan Aravot; P Suresh Jayasekara; Christa E Müller; Kenneth A Jacobson; Asher Shainberg
Journal:  Purinergic Signal       Date:  2013-07-05       Impact factor: 3.765

7.  Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease.

Authors:  Dony Maiguel; Mohd Hafeez Faridi; Changli Wei; Yoshihiro Kuwano; Keir M Balla; Dayami Hernandez; Constantinos J Barth; Geanncarlo Lugo; Mary Donnelly; Ali Nayer; Luis F Moita; Stephan Schürer; David Traver; Phillip Ruiz; Roberto I Vazquez-Padron; Klaus Ley; Jochen Reiser; Vineet Gupta
Journal:  Sci Signal       Date:  2011-09-06       Impact factor: 8.192

8.  Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Authors:  Roheena Z Panni; John M Herndon; Chong Zuo; Samarth Hegde; Graham D Hogg; Brett L Knolhoff; Marcus A Breden; Xiaobo Li; Varintra E Krisnawan; Samia Q Khan; Julie K Schwarz; Buck E Rogers; Ryan C Fields; William G Hawkins; Vineet Gupta; David G DeNardo
Journal:  Sci Transl Med       Date:  2019-07-03       Impact factor: 17.956

9.  Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

Authors:  Mohd Hafeez Faridi; Mehmet M Altintas; Camilo Gomez; Juan Camilo Duque; Roberto I Vazquez-Padron; Vineet Gupta
Journal:  Biochim Biophys Acta       Date:  2013-02-26

Review 10.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.